Kornimate/medical-research-clean huggingface dataset:
preventing cognitive and functional decline among seniors at risk

Conditions: Subjective Cognitive Decline

Summary: this study evaluates the efficacy of real-world strategy training (rwst) compared to a psycho-education workshop for improving everyday life performance in older adults with subjective cognitive decline (scd). participants will be randomly assigned to receive one of these approaches.

evidence suggests that 25-50% of community-dwelling older adults report scd and that these individuals have an elevated risk for developing mild cognitive impairment and/or dementia. many of these individuals report difficulties with complex activities of daily living. rwst aims to reduce these difficulties in everyday life by providing a meta-cognitive training approach that compensates for age-related executive changes. the approach is provided within the context of individually identified everyday-life difficulties. the psycho-education approach is a brain-health workshop supplemented by intellectually stimulating activities such as doing sudoku and/or word searches. this approach provides information people may use to inform health behaviour changes.

Eligibility criteria:
inclusion criteria: * have subjective cognitive complaints * be fluent in written and spoken english * able to self-identify areas of their everyday lives in which they would like to improve. exclusion criteria: * diagnosis of neurological conditions (e.g. dementia, mild cognitive impairment, parkinson's) * presence of severe depression * presence of substance abuse * history of hospitalization for psychiatric reasons

Keywords: age-related cognitive changes
post-ibrutinib colitis and intestinal microbiota

Conditions: Gastrointestinal Microbiome

Summary: identify gut microbiome biomarkers associated with colitis in patients treated with targeted therapy in hematology


Eligibility criteria:
inclusion criteria: * age 18 years * outside the context of guardianship, -affiliated to the social security regime and * having consented to participate in the colmi study. * patient who benefit of treatment by targeted therapy to ibrutinib exclusion criteria: * history of uncontrolled colitis before the start of treatment. * patient with inflammatory bowel disease. * patient not consenting to participate.

Keywords: gut microbiome hematologic malignancies b biomarkers targeted therapy gut microbiota
study of therapeutic effect of electret static physiotherapy film on acute soft tissue closed injury

Conditions: Soft Tissue Injuries

Summary: the aim of this study was to evaluate the efficacy and safety of electret static physiotherapy film developed by beijing youshilin science and technology development co., ltd., to treat acute soft tissue injury by sticking to the affected area

design of randomized, open, parallel controlled non inferiority clinical trial.a total of 60 patients were included in the trial, including 30 subjects in the experimental group and 30 subjects in the control group. the experimental disease was acute soft tissue closed injury.

Eligibility criteria:
inclusion criteria: * patients with acute soft tissue injury diagnosed by western medicine * ability to communicate well with the researcher and comply with the requirements of the validation * participants agreed to participate in the clinical validation and follow the validation program requirements, and signed the informed consent form exclusion criteria: * there are important organs (heart and lung) serious disease history, or have autoimmune disease history, such as rheumatism, sle, or have a history of immune dysfunction, such as suffering from aids * patients with cardiac pacemaker * patients with open wounds * pregnant and lactating women * patients with history of mental illness * participants participated in other medical device trials or drug clinical trials within three months * the researchers believe that the participants who are not eligible for clinical validation should be considered * patients who need to be treated with drugs * patients requiring physical therapy
observational study on endometrial stromal tumors

Conditions: Endometrial Stromal Tumors

Summary: observational, retrospective and prospective study on endometrial stromal tumor (est)

observational, retrospective and prospective study on est aimed to understand more about its biology, natural history and antitumor activity of different treatment options. this study will collect data in prospective and retrospective way of patients affected by est and treated according disease guidelines and local practices. the study will also review the diagnosis by a central expert pathologist in order to its confirmation

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of endometrial stromal tumor (est) according to the world health organization (who) classification 2003 or 2014 * informed consent signature exclusion criteria: * patients with different diagnosis from est
description of eosinophilic pneumonia in bji/pji treated by daptomycin

Conditions: Dactinomycin Adverse Reaction; Bone and Joint Infection

Summary: daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. its spectrum concerns gram-positive bacteria. since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in europe and worldwide. the purpose of this study is to describe the mechanism of occurrence of this ae with dapto; prolonged exposure and accumulation at the alveolar level could potentially have a role. better understanding the mechanisms of appearance of this ae would provide predictive elements making it possible to limit the occurrence of this ae in the future

daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. its spectrum concerns gram-positive bacteria. the infectious diseases society of america recommends the use of daptomycin 6 mg / kg / day in the second-line treatment of ioa on staphylococcal but also enterococcal prostheses, as an alternative to vancomycin and linezolid. in case of renal failure, daptomycin is often considered as a good therapeutic alternative to glycopeptides. since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in europe and worldwide. although a large proportion of cases have been reported in patients receiving daptomycin in unapproved indications, the use of daptomycin in authorized indications has also been associated with this risk. the dosage of daptomycin makes it possible to evaluate its effectiveness and prevent the occurrence of a overdose, provider of side effects. the purpose of this study is to describe the mechanism of occurrence of this ae with dapto; prolonged exposure and accumulation at the alveolar level could potentially have a role. better understanding the mechanisms of appearance of this ae would provide predictive elements making it possible to limit the occurrence of this ae in the future

Eligibility criteria:
inclusion criteria: * patients having had an eosinophilic pneumonia under daptomycine given to treat an osteoarticular infection (bji/pji) exclusion criteria: -

Keywords: eosinophilic pneumonia daptomycin bone and joint infection adverse event
demonstrate the safety and preformance of the srs device for the treatment of pelvic organ prolapse

Conditions: Anterior Vaginal Wall Prolapse; Vaginal Apex/Uterine Prolapse

Summary: a prospective, single arm, pre-market, multi-center clinical study to evaluate the safety and performance of the srs (lyra medical) vaginal mesh in pop patients


Eligibility criteria:
inclusion criteria: 1. patient has signed the informed consent form and is willing to participate in the clinical study and data collection. 2. patient age is between 18 and 75 years old 3. pop-q: aa and/or ba is at least -1 exclusion criteria: 1. patient is pregnant or breastfeeding 2. patient suffering from active infection (on antibiotic therapy) 3. patient planning vaginal delivery 4. patient had previous vaginal mesh surgery 5. patient is in high risk for surgery (evidence of clinically significant cardiovascular, renal, hepatic or respiratory diseases). 6. any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results. 7. malignancy . 8. known hypersensitivity to peek and polypropylene materials. 9. participation in another investigational trial that has not completed the primary endpoint or interferes with study participation. 10. tendency for hyper-scaring reaction 11. diagnosed with mental or emotional disturbance.
olanzapine improves the chemotherapy tolerance of advanced gastric cancer

Conditions: Gastric Cancer

Summary: to explore whether adding olanzapine to paclitaxel chemotherapy could improve chemotherapy tolerance and improve patient quality of life and prolong treatment failure time (ttf) in advanced gastric cancer after failure of first-line chemotherapy. this is a multi-center prospective randomized controlled open clinical study. patients will formally be enrolled after they had been screened and signed informed consent. baseline examinations will be started after entry into the group. those who meet the criteria for inclusion and exclusion were dynamically randomized at 1: 1. the experimental group will receive olanzapine and paclitaxel until treatment failure and the control group will receive paclitaxel until treatment failure.


Eligibility criteria:
inclusion criteria: 1. sign written informed consent; 2. age more than 18 years of age; 3. histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction; 4. locally advanced recurrent or metastatic disease; 5. have received systemic first-line chemotherapy and confirmed first-line treatment failure (platinum combined with fluorouracils); 6. subjects' baseline blood routine and biochemical indicators meet the following criteria hemoglobin ≥90g/l the absolute neutrophil count (anc) is ≥1.5×10\^9/l. platelets ≥100×10\^9/l alt, ast ≤ 2.5 times the normal upper limit, ≤ 5 times the normal upper limit (with liver metastasis) alp≤2.5 times normal upper limit, ≤ 5 times normal upper limit (with liver or bone metastases) serum total bilirubin \<1.5 times normal upper limit serum creatinine \<1.5 times normal upper limit serum albumin ≥30g/l 7. kps score ≥ 60 points; 8. life expectancy ≥ 3 months. exclusion criteria: 1. does not meet the above selection criteria; 2. the first-line treatment uses paclitaxel-based drugs; 3. pregnancy and lactation women; 4. allergies to research drugs or people with metabolic disorders; 5. history of organ transplantation (including bone marrow autologous transplantation and peripheral stem cell transplantation); 6. those who have been receiving systemic steroids for a long period of time (note: short-term users may be discontinued \>2 weeks for inclusion); 7. brain metastasis; 8. with severe infections need treatment; 9. accompanied by dysphagia active peptic ulcer complete or incomplete intestinal obstruction active gastrointestinal bleeding perforation etc; 10. severe liver diseases (such as liver cirrhosis etc.) kidney disease respiratory diseases or chronic diseases such as diabetes high blood pressure that cannot be controlled; 11. having other malignant tumors within 5 years except non-melanoma skin cancer and cervical cancer in situ; 12. heart disease with markedly abnormal electrocardiogram or clinical symptoms such as congestive heart failure marked coronary heart disease uncontrolled arrhythmia high blood pressure or previous myocardial infarction within 12 months or cardiac function class iii or iv.

Keywords: olanzapine gastric cancer tolerance
study on the influence of climatic and environmental factors on respiratory diseases in sanya, hainan province, china.

Conditions: Asthma; Allergic Rhinitis; Chronic Obstructive Pulmonary Disease(COPD); Atopic Dermatitis; Eczema; Urticaria; Bronchitis; Bronchiectasis Adult; Emphysema

Summary: to investigate the influence of climatic and environmental factors on respiratory or allergic diseases in sanya.

the study is an observational research, which will recruit the community migratory old people and children at school using cluster sampling in sanya by sanya maternal and child health care hospital (sanya women and children's hospital). sanya central hospital(hainan third people's hospital) and people's hospital of sanya will assist to diagnose old people disease. the data of climate and environment will be obtained from sanya meteorological administration and sanya municipal ecology and environment bureau. 1. the primary purpose is to investigate the influence of the unique tropical climate and environmental factors on the migratory old people with diseases such as asthma, allergic rhinitis, copd or atopic dermatitis in sanya from northern china, and to provide scientific evidence for publicity of the tourism and the health care industry. 2. the secondary purpose is to investigate prevalence and risk factors of asthma, allergic rhinitis and atopic dermatitis among children in sanya, which will provide a base for prevention and control strategies. 3. the third purpose is to retrospectively analyze the influence of climate and environmental factors in sanya on children with asthma, allergic rhinitis and atopic dermatitis in the past decade, and a comparative analysis of the incidence on children in sanya and shanghai.

Eligibility criteria:
inclusion criteria: * 50-80 years-old migratory people with asthma, allergic rhinitis, copd or atopic dermatitis from northern china; * 3-12 years-old children in sanya; * agree to participate this study. exclusion criteria: * disagree to participate this study; * having other respiratory diseases which can influence airflow, such as lung cancer, tuberculosis, pneumonia, bronchiectasis, etc; * inability to understand the study procedures or inability/reluctance to answer questionnaire judged by the investigator.

Keywords: asthma allergic rhinitis climatotherapy chronic obstructive pulmonary disease(copd) atopic dermatitis climate environment
study on fatigue- and hand-foot syndrome-related quality of life in patients with metastatic renal cell carcinoma receiving a tyrosine kinase inhibitor as first-line treatment

Conditions: Metastatic Renal Cell Carcinoma

Summary: the purpose of this study is to know about the quality of life of patients with metastatic renal cell carcinoma who are being treated with sunitinib, pazopanib or sorafenib, and who suffer from fatigue and hand-foot syndrome, with personal inter-variability, and to explore measures that can be taken in terms of both everyday lifestyle and treatment to mitigate or cure such side effects that affect patients.

prospective, multicentre, observational study in patients with metastatic renal cell carcinoma (mrcc) receiving a tyrosine kinase inhibitor as first-line treatment according to routine clinical practice, designed to evaluate the incidence of fatigue and hand-foot syndrome in order to determine how these affect the baseline characteristics of the patient and his/her disease (age, gender, baseline status, tumour histology, etc.) and the patient's lifestyle as such side effects develop. an exploratory analysis will be performed of measures that clinicians may adopt to improve patients' quality of life with regards to daytime naps, medication administration time, off-treatment periods, dose reductions and treatment breaks.

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years old and diagnosed with metastatic rcc who, in the investigator's opinion, are candidates for starting first-line treatment with a tyrosine kinase inhibitor according to routine clinical practice. * patients who have no contraindications to the treatment. * baseline ecog ≤ 2. * patients who are able to give informed consent on their own without the need for a legal representative. * committed patients who are able to complete the quality of life questionnaires and patient diary on their own without the need for a legal representative. exclusion criteria: * patients who are not candidates for first-line treatment with a tyrosine kinase inhibitor. * patients who are receiving the treatment as second-line or subsequent therapy. * untreated hypothyroidism. * untreated severe anaemia. * pregnancy or breast-feeding. * myocardial infarction or cerebrovascular accidents (cva) within the last 6 months. * severe hepatic impairment. * concomitant use of potent inhibitors or inducers that interact with hepatic cytochrome cyp3a4.

Keywords: metastatic renal cell carcinoma
betamethasone versus ketorolac injection for the treatment of dequervains tenosynovitis

Conditions: DeQuervain Tendinopathy

Summary: the purpose of this study is to determine if corticosteroid injection modifies the natural course of de quervain tendinopathy compared to a toradol injection.

if steroids are effective for dequervain tenosynovitis because of their anti-inflammatory properties, then there is a reasonable and rational argument to be made for the local injection of nsaids (non-steroidal anti-inflammatory drugs) into the first dorsal extensor compartment. ketorolac is an nsaid that has been proven efficacious in the treatment of another musculoskeletal condition. moreover, compared to betamethasone (or other injectable corticosteroids), injection of ketorolac decreases the patient exposure to the potential side-effects of corticosteroids, especially that of elevation of blood sugar levels in diabetics.

Eligibility criteria:
inclusion criteria: * diagnosis of dequervain tendinopathy * understands the local language and is willing and able to follow the requirements of the protocol * understands the informed consent and signs the institutional review board/independent ethics committee (irb/iec) approved informed consent form exclusion criteria: * patients who have an allergy to lidocaine, celestone, or ketorolac, nonsteroidal anti-inflammatory drugs (nsaids), or acetylsalicylic acid (asa) * patients who have an adverse reaction to lidocaine, celestone, or ketorolac (such as severe elevation of blood sugars in diabetics that caused medical complication) * patients who have received a prior steroid injection within the past three months * patients who have had a prior ipsilateral surgery for dequervain tenosynovitis * patients that have a skin lesion at the location of injection (such as trauma, eczema, rash) * patients who have a current infection at the location of injection * patients who have had iontophoresis within three months * patients who are breast feeding, pregnant, or who plan to become pregnant in the next six months
impact of neurostimulation on patterns of brain electrical activity in patients with tinnitus

Conditions: Tinnitus

Summary: relating the electroencephalogram findings of patients with tinnitus before and after a therapeutic modality is still scarce in the literature, especially with neuromodulatory methods, more specifically with transcranial direct current stimulation - tdcs. this study is a double blind, sham-controlled clinical trial aiming investigate the impact of tdcs on patterns of brain electrical activity in patients with chronic tinnitus. 36 volunteers with tinnitus will be allocated randomly in 2 groups: the first (n = 18) will receive anodic tdcs in the temporoparietal left area and cathode in the right dorsolateral prefrontal cortex and the second group (n = 18) correspond to the sham group. in addition, healthy individuals (n = 18) will be recruited for comparative purposes of brain electrical activity with and without tinnitus, totaling 54 participants. patients with tinnitus will receive transcranial direct current stimulation for 20 minutes for 5 consecutive days (1 week) and will be assessed before and after intervention by electroencephalogram, acuphenometry, visual analogue scale - vas and questionnaire tinnitus handicap inventory- thi. follow-up of volunteers will also be performed after 1 month of the end of treatment with tdcs.


Eligibility criteria:
inclusion criteria: * age of at least 18 years; * chronic tinnitus for at least 6 months. * age-adjusted normal (sensorineural) hearing exclusion criteria: * pregnancy and/or lactation; * concurrent treatment for tinnitus; * prior exposure to transcranial direct current stimulation (tdcs); * history of epilepsy and/or seizures; * electronic implants or metallic objects in body; * skin conditions where electrodes will be applied; * major neurological co-morbidities.

Keywords: tinnitus electroencephalogram transcranial direct current stimulation
identification and verification of candidate genes responsible for optic disc drusen development

Conditions: Optic Disk Drusen

Summary: the goal of this observational study is to learn about the genetic background for the development of optic disc drusen. the main question is: • can one or more candidate genes be found? participants will have a blood sample taken and answer a questionnaire.

the study is an international collaboration between university of utah, university of sydney, university of valladolid, and university of copenhagen. patients with optic disc drusen from 15 known optic disc drusen-families from different countries (usa, australia, spain and denmark) are participating in this study. blood samples are drawn from each patient and their affected and unaffected family members, and dna will be extracted. the investigators will do an optical coherence tomography-scan (according to odds consortium guidelines), and the participant will be asked to fill out the visual function questionnaire (vfq-25) including four additional questions about optic disc drusen. the etiology of optic disc drusen will be analyzed with a whole exome sequencing (wes), with the use of next generation sequencing (ngs). prior to wes, all participants will receive genetic counseling by a consultant to ensure awareness of possible secondary genetic findings.

Eligibility criteria:
inclusion criteria: * adult patients over the age of 18, who are capable of giving consent * diagnosis of optic disc drusen and a minimum of 3 optic disc drusen-affected family members exclusion criteria: * less than 3 affected family members * under the age of 18 or mentally disabled

Keywords: optic disc drusen genetics
ultrasonography in confirming proper position of endotracheal tube

Conditions: Endotracheal Tube Wrongly Placed During Anesthetic Procedure

Summary: the purpose of this study is to assess the applicability of using ultrasonography in confirmation of the position of the endotracheal tube (ett) after intubated to patients.

to assess the applicability of using ultrasonography as compared to routine portable cxr in confirmation of ett position. to determine the accuracy of ultrasonography in measuring the depth of ett as compare to standard cxr method.

Eligibility criteria:
inclusion criteria: * age \>18 years old with either endotracheal or nasotracheal intubation * having normal airway anatomy * performed portable cxr after intubation exclusion criteria: * presence in history of neck radiation, cervical spine immobility/instability * unstable vital signs * unwilling to participate or denial of informed consent

Keywords: ultrasonography us confirming confirmation proper position endotracheal tube ett emergency department ed applicability accuracy